Royalty Report: Drugs, Disease, Therapeutic – Collection: 237214

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 11

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Diagnostic
  • Defense/Military
  • Enzymes
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 237214

License Grant
The Japanese Licensor grants an irrevocable, exclusive (even as to Licensor) license under the Licensor Intellectual Property, including the right to grant sublicenses, to practice the Licensor Intellectual Property, and to develop, make, have made, use, offer for sale, market, sell, import, and distribute Product into and throughout the Licensee Territory in the Field.

Licensor grants a co-exclusive license with Licensor under the Licensor Intellectual Property, including the right to grant sublicenses, to make and have made the Compound solely for the formulation anywhere in the world of Product intended for importation, marketing, distribution, use, offer for sale, and sale by each Party in each Partys respective Territory.

License Property
The Compound shall mean the chemical compound known as [5-[3-.(2S)~{I,4-benzodioxan-2-ylmethyl) amino) propoxy]-I,3.;.benzodioxel hydrochloride] and designated [MKC-242], and [any isomer, salt, hydrate, solvate, metabolite, or prodrug of any of the foregoing].

MN-305 is a serotonin receptor agonist with high affinity and selectivity for the serotonin 5-HT1A receptor subtype. Drugs that act through this mechanism, such as buspirone, have been proven to be clinically effective in treating Generalized Anxiety Disorder.

Field of Use
The Field shall mean any use of Compound or Product in the prophylaxis, palliation, diagnosis or treatment of any human disease.

IPSCIO Record ID: 203342

License Grant
Japanese Licensor hereby grants to Licensee and its Affiliates an irrevocable, exclusive (even as to Licensor) license under the Licensor Intellectual Property, including the right to grant sublicenses, to practice the Licensor Intellectual Property, and to develop, make, have made, use, offer for sale, market, sell, import, and distribute the Product in the Licensee Territory in the Field.

Japanese Licensor hereby grants to Licensee and its Affiliates an irrevocable, exclusive (even as to Licensor) license in the Licensee Territory under the Licensor Intellectual Property, including the right to grant sublicenses, to practice the Licensor Intellectual Property, and to develop, make, have made, use, offer for sale, market, sell, import and distribute the Compound, solely for the formulation of Product intended for importation, marketing, distribution, use, offer for sale, and sale by Licensee, its Affiliates and its sublicensees in the Licensee Territory and/or, if the provisions are applicable, for the formulation of Product in the Licensor Territory.

License Property
Intellectual Property relates to the development and commercialization of MN-305.  MN-305 is for the treatment of anxiety, for which we commenced a Phase II clinical trial at the end of 2004.

Licensor Intellectual Property shall mean all intellectual property and proprietary rights in (i) all Licensor Patent Assets and (ii) all Licensor Know-How.

Licensor Patent Assets shall mean (i) those Patent Assets listed, including any patents issuing thereon, and (ii) all Patent Assets owned or controlled by Licensor or its Affiliates, in the Licensee Territory, during the term of this Agreement which, absent the rights granted to Licensee and its Affiliates hereunder, would be infringed by the research, development, manufacture, use, importation, sale or offer for sale of a Compound or a Product.

6069176 – Phenylethanolamine compounds useful as .beta. 3 agonists, process for producing the same, and intermediates in the production of the same.

Product shall mean any product in final form, packaged and labeled for commercial sale by prescription, or by any other method (or, where the context so indicates, the product being tested in clinical trials), which contains Compound as the sole therapeutically active ingredient in any dosage form or package configuration.

Compound shall mean a chemical compound which is (i) known as {ethy1.3-(IR,3R)-3-{(2R)-2-(3-chlorophenyl)-2-hydroxyethylamino}cyclohexyl}-phenoxyacetate maleate} and designated TT-138 (the “Main Compound”), as diagrammed on Schedule 1.10 hereto, and any isomer, salt, hydrate, solvate, metabolite, or prodrug of any of the foregoing, or (ii) disclosed or claimed in the Licensor Patent Assets listed hereto.

Field of Use
Field shall mean any use of Compound or Product in the prophylaxis, palliation, diagnosis or treatment of any human disease.

MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by Licensee for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD).

IPSCIO Record ID: 257486

License Grant
The Swiss Licensor grants an Exclusive sublicense in the Field under the Patents, to the extent, but only to the extent, that such patents or patent applications claim the Compound or Product or the manufacture, formulation, or use thereof, and Know-How to develop, have developed, make, have made, use, import, sell, offer for sale and have sold the Compound and Product in the Territory, subject to the terms and conditions of this Sublicense Agreement.

Licensor grants a non-exclusive, worldwide sublicense to make or use any analytical reference standards, intermediate or metabolite of the Compound or Product which may be claimed in Patents limited solely to making or using the Compound or Product.

Licensee represents and warrants that during the term of this Sub license Agreement, neither it, an Affiliate or a Sublicensee shall license, develop, have developed, manufacture, have manufactured, sell or have sold any of the following compounds or products classified as an atypical antipsychotic: i.e. Olanzapine, Sertindole, Seroquel, Ziprasadone, Risperidone.

License Property
Licensor has rights to certain patents and patent applications, and know-how relating to a compound known as Iloperidone.

Compound shall mean the chemical compound known as Iloperidone, whose specific chemical name is 1 -[ 4-(3-[ 4-(6-fluoro-l ,2-benzisoxazol-3-y 1)-1-piperidinyl]propoxy ]-3-methoxyphcnyl]ethanone, including any salts, hydrates, solvates, and/or stereoisomers thereof, and only the metabolites listed hereto, including any salts, hydrates, solvates and/or stereoisomers of such metabolites.

Field of Use
The Field shall mean application to all conditions, disorders and diseases in humans.  The licensed property use is for therapeutic treatment of schizophrenic patients.

IPSCIO Record ID: 233451

License Grant
Licensor grants a worldwide, exclusive license, with the right to sublicense, under the Licensors Rights, to Develop, make, have made, use, sell, offer for sale, have sold and import the Compound and Products in the Field, and otherwise to perform its obligations expressly set forth in this Agreement and the Co-Promotion Agreement.
License Property
The Compound means either (a) the Initial Compound or (b) any compound that is claimed in U.S. Patent No. 6,288,122 Bl and any hydrates, anhydrides, solvates, salts, esters or polymorphs thereof.

The initial compound means the compound ICA-17043 having the molecular structure set forth and any hydrates, anhydrides, solvates, salts, esters, isomers, prodrugs, metabolites or polymorphs thereof.

The Product means a pharmaceutical product that contains, incorporates or is comprised of the Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration thereof.

The Licensor Patents means all Patents, other than CMCC Patents, Controlled by Licensor as of the Effective Date or during the Term, that, absent rights thereunder, would be infringed by the Development, Manufacture, formulation, use, distribution, importation, sale, or offer for sale of Compound or Product, including without limitation any such Patents claiming the composition of matter or the use of Compound or Product or any Improvements thereto.

Licensors know-how means all Information, except for CMCC Know-How, that Licensor Controls as of the Effective Date or during the Term.

Field of Use
The field means prevention and treatment of all human and animal diseases and disorders.  The licensed technology is for use of these compounds include treating sickle cell disease, preventing erythrocyte dehydration and inhibiting potassium flux.

IPSCIO Record ID: 211925

License Grant
The Canadian Licensor grants an exclusive license under the Licensors Technology to use, market, advertise, promote, distribute, offer for sale, sell, manufacture, have manufactured, export and import, and co-develop the Product in the Territory for use in the Field with the right to sublicense.
License Property
The license includes patent rights and know-how for the compound.

The product is the proprietary compound known as ORI-9020.  ORI-9020 means ORI-9020 and its analogs, the chemical composition of which are described in the patent and any prodrug, metabolite, analog, salt, hydrate, solvate, polymorph, chimeric or inverted chimeric or isomer of ORI-9020.

Field of Use
The Field means the use of Product in the diagnosis and/or treatment of Hepatitis B infection.

IPSCIO Record ID: 239024

License Grant
The Licensor of Spain grants to an exclusive, even as to Licensor, license under the Patent Assets and the Licensor Know-How, including the right to grant sublicenses, to develop, make, have made, use, import, offer for sale, promote, market, commercialize, distribute and sell Product in the Territory, and insofar as necessary for the purposes of exercising such rights, to develop, make, have made, use, import, offer for sale, commercialize, distribute and sell Compound.
License Property
The compound is UR-12746 Sodium Salt, meaning UR-12746 (including UR-12715) and UR-12746(S), and any derivative, homolog or analog of any of the foregoing or any isomer, salt, hydrate, solvate, amide, ester, metabolite, or prodrug of any of the foregoing, and any pharmaceutical composition containing any of the foregoing in any pharmaceutically acceptable form.

Licensor possesses significant expertise in the field of antiinflammatory therapeutics, and dersalazine represents the culmination of years of internal research.

Dersalazine is a new chemical entity that combines a well-known anti-inflammatory agent, 5-ASA, with a novel potent agent that acts as a PAF antagonist and an inhibitor of key interleukin cytokines to achieve a synergistic therapeutic effect when compared to the activities of each component separately. Chemical cleavage of dersalazine by colonic bacteria releases the two active compounds for the topical treatment of inflammation in the colon. The 5-ASA molecule contained in dersalazine has known antioxidant properties which may ameliorate the deleterious inflammatory effects ascribed to the overproduction of free radicals.

Field of Use
Dersalazine is a compound in early clinical development to treat Inflammatory Bowel Disease (IBD), which includes ulcerative colitis and Crohn's disease.

IPSCIO Record ID: 204310

License Grant
This agreement is for the reversion to Licensee of the rights for the Commercialization of Compound and Products in the United States, including the rights to Commercialize Co-Formulation Products in the United States.

The Licensor of England grants back to Licensee the following licenses, with the right to grant sublicenses, under all Program Improvements and Program Patents:  
(i) a co-exclusive license to Develop Products in the Field and in the Territory,
(ii) subject to Licensor’s rights and obligations to Manufacture Products for Development activities, an exclusive license, exclusive even as to Licensor, to make and have made and otherwise Manufacture Compound and Products, other than Co-Formulation Products, in the Field and anywhere in the Territory for the Licensee Territory; and
(iii) an exclusive license, exclusive even as to Licensor, to use, sell, offer for sale, import and otherwise Commercialize Products in the Field in the Licensee Territory.

Licensor grants the following licenses, with the right to grant sublicenses, under the Co-Formulation Product IP:
(i) a co-exclusive license to Develop Co-Formulation Products in the Field in the Territory, and
(ii) an exclusive license, exclusive even as to Licensor, to use, sell, offer for sale, import and otherwise Commercialize Co-Formulation Products in the Field in the Amicus Territory.

Licensor grants to Licensee a worldwide, non-exclusive, right and license, with the right to grant sublicenses,
(a) under Licensor’s and its Affiliates’ rights in the Program Patents to make, have made, use, sell, offer for sale, and import products, and to otherwise practice and exploit the Program Improvements and
(b) under Licensor’s and its Affiliates’ rights in the Patents within the Co-Formulation Product IP to make and have made, other than JR051 or Co-Formulation Product in which the ERT enzyme is JR051, use, sell, offer for sale and import products, other than JR051, and to otherwise practice and exploit the Patents within the Co-Formulation Product IP claimed in such Program Patents and/or Patents within the Co-Formulation Product IP.

In the original agreement, Amicus granted to Licensee exclusive, worldwide, rights to Compounds and Products (each as defined below) and pursuant to which Amicus and GSK have collaborated and are collaborating on the Development of the Compound and Product;

License Property
The Compound means migalastat, and includes (a) any compounds with alternative names but with the same chemical structure as migalastat, and (b) any metabolites, prodrugs, isomers and enantiomers, excluding the isomer/enantiomer 1-deoxynorjirimycin or (2R,3R,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol, esters, salts, hydrates, solvates, and polymorphs thereof, whether alone or in a mixture.

The Co-Formulation Product ERT Enzyme means JR051; or any other alpha Galactosidase A enzyme selected by the Parties to be used as a ERT enzyme in co-formulation with the Compound.  ERT means enzyme replacement therapy.

Co-development of all current and future formulations of migalastat HCl for Fabry disease, including a co-formulation of migalastat HCl with Licensee’s investigational enzyme replacement therapy (ERT) for Fabry disease.

Fabry disease is a rare genetic disease a deficiency of the enzyme alpha-galactosidase A (a-Gal A) that causes a buildup of a type of fat called globotriaosylceramide (Gb3, or GL-3) in the body. Fabry disease is classified as a type of lysosomal storage disorder.

Field of Use
The Field means any and all uses or purposes, including, without limitation, the treatment, palliation, and/or prevention and diagnosis of any human or animal disease, disorder or condition, including use of a Product in combination with ERT.

IPSCIO Record ID: 215205

License Grant
This agreement is for the reversion to Licensor of the rights for the Commercialization of Compound and Products in the United States, including the rights to Commercialize Co-Formulation Products in the United States.

Licensor grants to the English Licensee the following licenses, with the right to grant sublicenses, under the Licensor Technology:  a co-exclusive license, co-exclusive with Licensor, to Develop Products in the Field in the Territory, and, an exclusive license to make, have made and otherwise Manufacture Compound and Products in the Field and anywhere in the Territory for the Licensee Territory; and,  an exclusive license to make, have made and otherwise Manufacture Co-Formulation Products in the Field and anywhere in the Territory for the Licensor Territory; and, an exclusive license to Manufacture Compound and Products for use in connection with Development activities; and, an exclusive license to use, sell, offer for sale, import and otherwise Commercialize Products in the Field in the Licensee Territory.

License Property
Compound means migalastat, and includes any compounds with alternative names but with the same chemical structure as migalastat, and any metabolites, prodrugs, isomers and enantiomers (excluding the isomer/enantiomer “1-deoxynorjirimycin” or “(2R,3R,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol”), esters, salts, hydrates, solvates, and polymorphs thereof, whether alone or in a mixture.

The Co-Formulation Product ERT Enzyme means JR051; or any other alpha Galactosidase A enzyme selected by the Parties, to be used as a ERT enzyme in co-formulation with the Compound.

ERT means enzyme replacement therapy.

Companies jointly to develop proprietary enzyme replacement therapy (ERT) for Fabry disease co-formulated with chaperone migalastat HCl.

Fabry disease is an inherited disorder that results from the buildup of a particular type of fat, called globotriaosylceramide, in the body's cells. Beginning in childhood, this buildup causes signs and symptoms that affect many parts of the body.

Field of Use
The Field means any and all uses or purposes, including, without limitation, the treatment, palliation, and/or prevention and diagnosis of any human or animal disease, disorder or condition, including use of a Product in combination with ERT.

IPSCIO Record ID: 233476

License Grant
The Japanese Licensor grants an exclusive license, with the right to grant sublicenses, under the Licensor Intellectual Property to use and develop the Compound in the Field in the Licensee Territory, and to make, have made, use, develop and sell, offer to sell and import the Product in the Field in the Licensee Territory.

This agreement also includes a non-exclusive grant back to Licensor.

License Property
Compound means the compound defined as (-)-bis(2{[2s]-2-({(2r)-2-hydroxy-2-{4-hydroxy-3-(2-hydroxyethyl)phenyl]ethyl}amino)-1,2,3,4-tetrahydronaphthalan-7-yl}oxy)-N,N-dimethylacetamide)  monosulphate,]  with the internal Licensor code name of [-1246] and any other compounds disclosed or included in, or covered by any of the Licensor Patents.

Product means any and all pharmaceutical preparations in the Field in any finished dosage packaged form for sale to Third Parties which contains the Compound or combinations thereof as at least one of the primary therapeutically active ingredients.

MN-221 is a novel, highly selective ß2-adrenergic receptor agonist for use in the treatment of premature labor.

Field of Use
Field means the treatment, palliation or prevention of disease, including premature labour in human beings.

IPSCIO Record ID: 204322

License Grant
Licensor grants to the English Licensee an exclusive license, with the right to grant sublicenses, under all Licensed Technology, to Develop, make, use, sell, offer for sale and import Compound and Products, in each case, solely in the Field and in the Territory.

Licensor grants a license, with the right to sublicense, in accordance with the terms of the Trademark License Agreement, to use the Licensor Trademark(s) in such country(ies) in the Territory in connection with the making, having made, use, sale, offering for sale, importation, packaging, distributing and promoting of Product in the Field and in such country(ies) in the Territory.

License Property
The Compound means migalastat, and includes any compounds with alternative names but with the same chemical structure as Migalastat, and any metabolites, prodrugs, isomers and enantiomers, excluding the isomer/enantiomer “1-deoxynorjirimycin” or “(2R,3R,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol”, esters, salts, hydrates, solvates, and polymorphs, whether alone or in a mixture.

Migalastat, trade name Galafold (formerly known as Amigal) is a drug for the treatment of Fabry disease, a rare genetic disorder.  Amigal, is an orally-administered, small molecule pharmacological chaperone for the treatment of Fabry disease.

Fabry disease is an inherited disorder that results from the buildup of a particular type of fat, called globotriaosylceramide, in the body's cells. Beginning in childhood, this buildup causes signs and symptoms that affect many parts of the body.

Field of Use
The Field means any and all uses or purposes, including, without limitation, the treatment, palliation, and/or prevention and diagnosis of any human or animal disease, disorder or condition, including use of the Product in combination with ERT or enzyme replacement therapy.

The specific treatment available for Fabry disease (FD) is enzyme replacement therapy (ERT) with agalsidase alfa or beta.

IPSCIO Record ID: 2809

License Grant
Licensor grants an exclusive, worldwide license to make, have made, use or sell the Compound and Product pursuant to all Licensor Intellectual Property Rights.
License Property
Licensor has discovered a compound internally designated as LY353433 which may be useful in the treatment of functional gastrointestinal disorders and other indications.

Compound means 1-(1-methylethyl)-N-[2-[4-[(tricyclo[3.3.1.1 (3,7)]-dec-1-ylcarbonyl)amino]-1-piperidinyl]ethyl]-1H-indazole-3-carboxamide and all pharmaceutically acceptable salts and solvates thereof.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.